Sara Buhrlage
Associate Professor, Biological Chemistry & Molecular Pharmacology Dana-Farber Cancer Institute
Seminars
Wednesday 21st October 2026
Expanding Covalent Targeting of Deubiquitinases: Leveraging Novel Warheads to Achieve Selective, In Vivo-Ready Inhibitors
9:30 am
- Exploring deubiquitinases as a tractable covalent target class, demonstrating how structural diversity enables surprising selectivity versus traditional enzyme families like kinases
- Leveraging novel and underexplored warheads (e.g., SNAr electrophiles, propargylamines, cyanamides) to access cysteine proteases beyond classical acrylamide chemistries
- De-risking emerging covalent chemotypes through integrated chemoproteomics and in vivo validation to achieve selective, exposure-ready compounds across oncology and antiviral programs
